β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation

[1]  Robin L. Jones,et al.  PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study , 2010, Modern Pathology.

[2]  I. Ellis,et al.  β-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast , 2010, Modern Pathology.

[3]  I. Tomlinson,et al.  Nuclear β‐catenin expression and Wnt signalling: in defence of the dogma , 2010, The Journal of pathology.

[4]  O. Olopade,et al.  Stem Cells , Tissue Engineering and Hematopoietic Elements Wnt /-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome , 2010 .

[5]  A. Ashworth,et al.  An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers , 2010, Breast Cancer Research and Treatment.

[6]  S. O'toole,et al.  Cytoplasmic Localization of β-Catenin is a Marker of Poor Outcome in Breast Cancer Patients , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[7]  B. Kreike,et al.  Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis , 2009, Breast Cancer Research and Treatment.

[8]  Nicholas J. Wang,et al.  Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. , 2009, Cancer research.

[9]  A. Ashworth,et al.  Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers , 2009, Clinical Cancer Research.

[10]  P. Argani,et al.  Most Basal-like Breast Carcinomas Demonstrate the Same Rb−/p16+ Immunophenotype as the HPV-related Poorly Differentiated Squamous Cell Carcinomas Which They Resemble Morphologically , 2009, The American journal of surgical pathology.

[11]  I. Ellis,et al.  Patho-biological aspects of basal-like breast cancer , 2009, Breast Cancer Research and Treatment.

[12]  O. Sieber,et al.  APC and the three-hit hypothesis , 2009, Oncogene.

[13]  A. Lazar,et al.  Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. , 2008, The American journal of pathology.

[14]  Robin L. Jones,et al.  Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients , 2008, Breast Cancer Research and Treatment.

[15]  A. Ashworth,et al.  Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast , 2008, The Journal of pathology.

[16]  J. Reis-Filho,et al.  Nestin is expressed in basal-like and triple negative breast cancers , 2008, Journal of Clinical Pathology.

[17]  T. Giordano,et al.  Genetic Changes of Wnt Pathway Genes Are Common Events in Metaplastic Carcinomas of the Breast , 2008, Clinical Cancer Research.

[18]  Robin L. Jones,et al.  Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis , 2008, Breast Cancer Research and Treatment.

[19]  Alan Mackay,et al.  Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines , 2008, Laboratory Investigation.

[20]  Gema Moreno-Bueno,et al.  Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. , 2008, Cancer research.

[21]  J. Reis-Filho,et al.  Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype , 2007, Journal of Clinical Pathology.

[22]  H. Juan,et al.  Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial–mesenchymal transition , 2007, Oncogene.

[23]  Robin L. Jones,et al.  Caveolin 1 Is Overexpressed and Amplified in a Subset of Basal-like and Metaplastic Breast Carcinomas: A Morphologic, Ultrastructural, Immunohistochemical, and In situ Hybridization Analysis , 2007, Clinical Cancer Research.

[24]  S. Lakhani,et al.  Metaplastic breast carcinomas are basal‐like tumours , 2006, Histopathology.

[25]  David L Rimm,et al.  Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. , 2006, Cancer research.

[26]  Robin L. Jones,et al.  Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis , 2006, Modern Pathology.

[27]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[28]  D. Rimm,et al.  β‐Catenin and p53 analyses of a breast carcinoma tissue microarray , 2004, Cancer.

[29]  M. Romeih,et al.  Wnt signaling in hepatocellular carcinoma: Analysis of mutation and expression of beta‐catenin, T‐cell factor‐4 and glycogen synthase kinase 3‐beta genes , 2003, Journal of gastroenterology and hepatology.

[30]  K. B. Pedersen,et al.  Expression of S100A4, E-cadherin, α- and β-catenin in breast cancer biopsies , 2002, British Journal of Cancer.

[31]  M. Hung,et al.  β-catenin interacts with and inhibits NF-κB in human colon and breast cancer , 2002 .

[32]  S. Hirohashi,et al.  Target disruption of the mutant β-catenin gene in colon cancer cell line HCT116: preservation of its malignant phenotype , 2002, Oncogene.

[33]  S. Wong,et al.  Expression of frizzled‐related protein and Wnt‐signalling molecules in invasive human breast tumours , 2002, The Journal of pathology.

[34]  D. Miles,et al.  Retention of the expression of E‐cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast , 2001, The Journal of pathology.

[35]  M. Hung,et al.  β-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression , 2000 .

[36]  A. Børresen-Dale,et al.  Re‐expression of E‐cadherin, α‐catenin and β‐catenin, but not of γ‐catenin, in metastatic tissue from breast cancer patients , 2000 .

[37]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[38]  Y. Nakamura,et al.  Transformation and morphological changes of murine L cells by transfection with a mutated form of beta-catenin. , 1999, Cancer research.

[39]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Boecker,et al.  Immunophenotypic and prognostic analysis of E‐cadherin and β‐catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44 , 1999, Histopathology.

[41]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[42]  A. Børresen-Dale,et al.  E‐cadherin and α‐, β‐, and γ‐catenin protein expression in relation to metastasis in human breast carcinoma , 1998 .

[43]  Bert Vogelstein,et al.  Mutational Analysis of the APC/β-Catenin/Tcf Pathway in Colorectal Cancer , 1998 .

[44]  T. Iwama,et al.  Coexistence of somatic and germ-line mutations of APC gene in desmoid tumors from patients with familial adenomatous polyposis. , 1993, Cancer research.

[45]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[46]  G. Azabdaftari,et al.  Refinement of breast cancer classification by molecular characterization of histological special types , 2009 .

[47]  S. Singletary,et al.  Breast Cancer Staging: Working With the Sixth Edition of the AJCC Cancer Staging Manual , 2006, CA: a cancer journal for clinicians.

[48]  Minoti Hiremath,et al.  Beta-catenin and Tcfs in mammary development and cancer. , 2003, Journal of mammary gland biology and neoplasia.

[49]  M. Hung,et al.  beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. , 2002, Cancer cell.

[50]  A. Krasinskas,et al.  Fibromatosis of the breast and mutations involving the APC/beta-catenin pathway. , 2002, Human pathology.

[51]  A. Krasinskas,et al.  Fibromatosis of the breast and mutations involving the APC/β-catenin pathway , 2002 .

[52]  M. Hung,et al.  Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[53]  A. Børresen-Dale,et al.  Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients [seecomments]. , 2000, The Journal of pathology.

[54]  F. McCormick,et al.  Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. , 1999, Nature.

[55]  A. Sparks,et al.  Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. , 1998, Cancer research.

[56]  A. Børresen-Dale,et al.  E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma. , 1998, The Journal of pathology.

[57]  D. Rimm,et al.  The expression of p120ctn protein in breast cancer is independent of alpha- and beta-catenin and E-cadherin. , 1998, The American journal of pathology.

[58]  H. Höfler,et al.  No evidence for mutations in the alpha- and beta-catenin genes in human gastric and breast carcinomas. , 1996, Cancer research.

[59]  H. Höfler,et al.  No Evidence for Mutations in the α- and β-Catenin Genes in Human Gastric and Breast Carcinomas , 1996 .